DK1531800T3 - Stealth-lipidnanokapsler, fremgangsmåder til fremstilling deraf som en bærer for aktivt princip(per) - Google Patents
Stealth-lipidnanokapsler, fremgangsmåder til fremstilling deraf som en bærer for aktivt princip(per)Info
- Publication number
- DK1531800T3 DK1531800T3 DK03757174.2T DK03757174T DK1531800T3 DK 1531800 T3 DK1531800 T3 DK 1531800T3 DK 03757174 T DK03757174 T DK 03757174T DK 1531800 T3 DK1531800 T3 DK 1531800T3
- Authority
- DK
- Denmark
- Prior art keywords
- nanocapsules
- lipid
- preparation
- lipid nanocapsules
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0207175A FR2840532B1 (fr) | 2002-06-11 | 2002-06-11 | Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s) |
US42111202P | 2002-09-09 | 2002-09-09 | |
PCT/IB2003/003213 WO2003103822A2 (en) | 2002-06-01 | 2003-06-11 | Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s) |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1531800T3 true DK1531800T3 (da) | 2011-07-11 |
Family
ID=29559140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03757174.2T DK1531800T3 (da) | 2002-06-11 | 2003-06-11 | Stealth-lipidnanokapsler, fremgangsmåder til fremstilling deraf som en bærer for aktivt princip(per) |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040076683A1 (da) |
AT (1) | ATE511834T1 (da) |
DK (1) | DK1531800T3 (da) |
ES (1) | ES2366978T3 (da) |
FR (1) | FR2840532B1 (da) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8383081B2 (en) * | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
US7829064B2 (en) | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
US8119101B2 (en) | 1999-05-10 | 2012-02-21 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
US8420086B2 (en) | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
US8883160B2 (en) * | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
US9550838B2 (en) | 2004-02-13 | 2017-01-24 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
FR2916974B1 (fr) | 2007-06-11 | 2010-11-26 | Univ Angers | Procede de preparation de nanoparticules lipidiques |
FR2916973B1 (fr) * | 2007-06-11 | 2010-02-26 | Univ Angers | Nanocapsules a coeur lipidique chargees en actif(s) hydrosoluble(s) ou hydrodispersible(s) |
FR2939699B1 (fr) | 2008-12-12 | 2011-05-06 | Univ Angers | Procede de preparation de nanoparticules lipidiques |
AU2011203890B2 (en) * | 2010-01-11 | 2013-05-30 | Center For Molecular Medicine And Immunology | Enhanced cytotoxicity of anti-CD74 and anti-HLA-DR antibodies with interferon-gamma |
ES2629187T3 (es) | 2011-04-20 | 2017-08-07 | The University Of Sydney | Material en forma de partículas y toxina celular para su uso en el tratamiento de un tumor sólido |
US9757458B2 (en) | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
US9192664B2 (en) | 2011-12-05 | 2015-11-24 | Immunomedics, Inc. | Therapeutic use of anti-CD22 antibodies for inducing trogocytosis |
US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
WO2014092804A1 (en) | 2012-12-13 | 2014-06-19 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
US9107960B2 (en) | 2012-12-13 | 2015-08-18 | Immunimedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
FR3017294B1 (fr) * | 2014-02-07 | 2021-10-01 | Atlangram | Nanoparticules lipidiques comprenant un antibiotique et leurs utilisations en therapie |
CN107428837A (zh) | 2015-04-22 | 2017-12-01 | 免疫医疗公司 | 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定 |
US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
CN115969970A (zh) | 2016-02-10 | 2023-04-18 | 免疫医疗公司 | Abcg2抑制剂与sacituzumab govitecan的组合 |
JP7379795B2 (ja) | 2016-04-27 | 2023-11-15 | イミューノメディクス、インコーポレイテッド | チェックポイント阻害薬に再発/耐性を示す腫瘍を治療するための抗Trop-2-SN-38抗体薬物複合体の効果 |
RU2758234C2 (ru) | 2017-03-27 | 2021-10-26 | Иммьюномедикс, Инк. | ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51 |
CN110352201A (zh) | 2017-04-03 | 2019-10-18 | 免疫医疗公司 | 用于癌症疗法的抗体药物缀合物的皮下施用 |
FR3099069A1 (fr) * | 2019-07-24 | 2021-01-29 | Université D`Angers | Procede continu de nano-emulsification par inversion de phase en concentration |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4839175A (en) * | 1986-07-28 | 1989-06-13 | Liposome Technology, Inc. | Liposomes with enhanced retention on mucosal tissue |
FR2608942B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules |
US5811119A (en) * | 1987-05-19 | 1998-09-22 | Board Of Regents, The University Of Texas | Formulation and use of carotenoids in treatment of cancer |
US4935491A (en) * | 1987-08-24 | 1990-06-19 | Board Of Regents, The University Of Texas System | Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine |
US5160669A (en) * | 1988-03-03 | 1992-11-03 | Micro Vesicular Systems, Inc. | Method of making oil filled paucilamellar lipid vesicles |
US5527528A (en) * | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
US6165500A (en) * | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US6143276A (en) * | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US6416740B1 (en) * | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
US6217886B1 (en) * | 1997-07-14 | 2001-04-17 | The Board Of Trustees Of The University Of Illinois | Materials and methods for making improved micelle compositions |
US6123923A (en) * | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
FR2805761B1 (fr) * | 2000-03-02 | 2002-08-30 | Mainelab | Nanocapsules lipidiques, procede de preparation et utilisation comme medicament |
AU2006299421B2 (en) * | 2005-10-03 | 2013-01-31 | Mark A. Pinsky | Compositions and methods for improved skin care |
-
2002
- 2002-06-11 FR FR0207175A patent/FR2840532B1/fr not_active Expired - Fee Related
-
2003
- 2003-06-11 US US10/458,324 patent/US20040076683A1/en not_active Abandoned
- 2003-06-11 ES ES03757174T patent/ES2366978T3/es not_active Expired - Lifetime
- 2003-06-11 AT AT03757174T patent/ATE511834T1/de active
- 2003-06-11 DK DK03757174.2T patent/DK1531800T3/da active
Also Published As
Publication number | Publication date |
---|---|
US20040076683A1 (en) | 2004-04-22 |
ES2366978T3 (es) | 2011-10-27 |
FR2840532A1 (fr) | 2003-12-12 |
ATE511834T1 (de) | 2011-06-15 |
FR2840532B1 (fr) | 2005-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1531800T3 (da) | Stealth-lipidnanokapsler, fremgangsmåder til fremstilling deraf som en bærer for aktivt princip(per) | |
WO2003103822A3 (en) | INDETECTABLE LIPID NANOCAPSULES, PROCESSES FOR THE PREPARATION THEREOF AND USE OF SUCH NANOCAPSULES AS A SUPPORT FOR ACTIVE INGREDIENT (S) | |
CY1120462T1 (el) | Τοπικες ανθελμινθικες κτηνιατρικες τυποποιησεις | |
WO2000040203A3 (en) | Polymeric delivery agents and delivery agent compounds | |
WO2002019969A3 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
CR7776A (es) | Conjugados de polimero con antigenicidad disminuida, metodos de preparacion y usos de los mismos | |
WO2000062813A3 (en) | Cationic peg-lipids and methods of use | |
WO2003043631A3 (en) | Method for identification of tumor targeting enzymes | |
GEP20063895B (en) | Platinum derivative pharmaceutical formulations | |
DK1187629T3 (da) | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid | |
JP2001247459A5 (da) | ||
SG148997A1 (en) | Powders comprising low molecular dextran and methods of producing those powders | |
WO2002053100A3 (en) | Pharmaceutical dosage form for oral administration of low molecular weight heparin | |
TR199900336T2 (xx) | EAA antagonistleri olarak tetrahidrokinolin t�revleri. | |
JP2009520814A (ja) | 放出制御ゲル | |
BRPI0515756A (pt) | sistema de fornecimento de quelador de ferro direcionado | |
AR043071A1 (es) | Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica | |
EP0992509A3 (en) | Novel macrolide derivatives | |
JP6482570B2 (ja) | 経皮吸収促進剤及び経皮吸収促進助剤 | |
WO2003041682A3 (en) | Lipid carrier compositions and methods for improved drug retention | |
ATE289801T1 (de) | Verabreichungssystem für wasserunlösliche arzneistoffe | |
BRPI0510694A (pt) | composições farmacêuticas compreendendo ingredientes ativos concentrados encapsuladas em gelatina mole | |
IS8428A (is) | Innrennslislyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn | |
CA2504873A1 (en) | Percutaneous absorption preparation containing 3-methyl-1-phenyl-2-pyrazolin-5-one | |
EP1325753A3 (en) | Bio-compatible means for controlled drug delivery to tissue and method of use |